AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06220175 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Xilocaine Spray Arm
Description: After Xilocaine Spray pharyngeal topical anestesia, upper GI endoscopy will be performed with a standard diameter tube, with SpO2 non invasive monitoring.
Study NCT06654830 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: RATT
Description: Robotic-assisted thoracoscopic thymectomy (RATT) will be performed using Da Vinci Robotic Surgical Systems.
Study NCT06654830 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: VATT
Description: Video-assisted thoracoscopic thymectomy (VATT) was performed using traditional thoracoscopic systems.
Study NCT06592508 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Remote Virtual Cardiology Program
Description: Ventricle Health Program, which is a remote, virtual, cardiology program that provides heart failure education to patients, monitors for worsening heart failure, and rapidly titrates heart failure medical therapy.
Study NCT04923893 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Bortezomib will be administered SC.
Study NCT04923893 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone will be administered orally.
Study NCT04923893 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Lenalidomide will be administered orally.
Study NCT04923893 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cilta-cel
Description: Cilta-cel infusion will be administered.
Study NCT04923893 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide will be administered intravenously.
Study NCT04923893 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine will be administered intravenously.
Study NCT06105554 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belumosudil mesylate
Description: Given by PO
Study NCT06605989 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Nasotracheal intubation
Description: For nasotracheal intubation, the nasal RAE tube will be first inserted through the left nostril for patients in the left nostril side arm. For nasotracheal intubation, the nasal RAE tube will be first inserted through the right nostril for patients in the right nostril side arm.
Study NCT05243680 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK3511294 (Depemokimab)
Description: GSK3511294 (Depemokimab) will be administered using a pre-filled safety syringe.
Study NCT06661681 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Functional Therapy (CFT)
Description: Cognitive Functional Therapy (CFT) is underpinned by a strong therapeutic alliance, active listening, and motivational interviewing style, covering the following domains:~i) Making sense of pain involves discussing the multidimensional nature of persistent pain, as well as the beliefs, emotions, and behaviors that can perpetuate the vicious cycle of pain and disability.~ii) Exposure with control involves a functional training designed to normalize maladaptive and provocative postural and movement behaviors, where individuals will learn strategies to improve their body awareness and control and modify postures and tasks commonly associated with pain.~iii) Lifestyle change aims to help patients embrace a healthy lifestyle, which will include promoting a gradual increase in physical activity, sleep hygiene counseling, stress management strategies, and social re-engagement.
Study NCT06661681 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Therapeutic exercises group
Description: Each session will include stretching exercises targeting the following muscles i) Upper trapezius; ii) Pectoralis minor; iii) Posterior shoulder region, and strengthening exercises targeting the following muscles i) Lower trapezius, ii) Middle trapezius, iii) Serratus punch exercise, iv) Shoulder external rotators, and v) Shoulder internal rotators.
Study NCT06663956 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: a patient self-reporting applet
Description: We propose to develop a patient self-reporting applet that is easy to use and simple to operate. The program is embedded with questionnaires related to cancer pain and quality of life assessment, so that patients can fill out the questionnaires to report their symptoms and changes in their conditions to primary care doctors in a timely manner. At the same time, the background of the program will monitor the patient's indicators in real time. When the patient's pain reaches moderate-to-severe level, or when the patient experiences side effects of drugs, or when the patient's adherence to medication is poor, the primary care doctor can immediately receive relevant alerts through the app, so as to intervene in the patient's cancer pain treatment. When the patient has an alarm value, primary care doctors can provide feedback to doctors in higher-level hospitals and implement comprehensive and standardized treatment for cancer pain patients.
Study NCT06036836 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: favezelimab/pembrolizumab
Description: IV infusion
Study NCT06036836 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pembrolizumab
Description: IV infusion
Study NCT06036836 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lenvatinib
Description: Oral administration of capsule
Study NCT05607004 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: (Z)-endoxifen
Description: (Z)-endoxifen capsules. Doses of (Z)-endoxifen to be evaluated include 20 mg (two x 10 mg capsules), 40 mg (one 40 mg capsule) and 80 mg (two x 40 mg capsules).
Study NCT06295783 — intervention group
Intervention type: OTHER
Intervention: MDASI-HN
Description: Given by Questionnaire
Study NCT06295783 — intervention group
Intervention type: OTHER
Intervention: EORTC QLQ-C30
Description: Given by Questionnaire
Study NCT06295783 — intervention group
Intervention type: OTHER
Intervention: EORTC HN35
Description: Given by Questionnaire
Study NCT04964934 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9833
Description: Dosage formulation: AZD9833 tablets will be administered orally
Study NCT05607004 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: exemestane
Description: exemestane tablets 25 mg
Study NCT05607004 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: goserelin
Description: goserelin 3.6 mg subcutaneous implant
Study NCT05607004 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: goserelin
Description: goserelin 3.6 mg subcutaneous implant
Study NCT04964934 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AZD9833 Placebo
Description: Dosage formulation: AZD9833 placebo tablets will be administrated orally.
Study NCT04964934 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anastrozole
Description: Dosage formulation: anastrozole tablets will be administered orally.
Study NCT04964934 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anastrozole placebo
Description: Dosage formulation: anastrozole placebo tablets will be administrated orally.
Study NCT04964934 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Letrozole
Description: Dosage formulation: letrozole tablets will be administered orally.
Study NCT04964934 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole placebo
Description: Dosage formulation: letrozole placebo tablets will be administered orally.
Study NCT06663280 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Digital health assistant ADELE
Description: The digital health assistant ADELE Blood Pressure A0007 (ADELE for short) improves the daily lives of patients with high blood pressure and enhances patient care. Participants in the intervention group were provided with ADELE to use during the study period for voice-based recording, interpretation and classification of their vital signs and body conditions.
Study NCT06664047 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: OTT ACLR
Description: Patients in this group will undergo a reconstruction with the OTT technique which includes an intra-articular component and an extra-articular one, functioning as a LET.
Study NCT06664047 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ACLR LET
Description: Patients in this group will undergo a reconstruction with the conventional ACL technique accompanied by a routine LET, obtained from the iliotibial band.
Study NCT06662487 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resistance Training
Description: Participants in the experimental group will perform free weight resistance training sessions focused on push, pull, and leg movement patterns. The program will last for 10 weeks, progressively increasing in load and intensity. The intervention will be designed to improve the participants' physical strength and observe how these changes affect their cognitive performance.
Study NCT04964934 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: Dosage formulation: palbociclib tablets/capsules will be administered orally
Study NCT06665139 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: muscle thickness
Description: Pain intensity will be measured with visual analog scale, sonographic severity grade of shoulder impingement syndrome, muscle thickness of serratus anterior muscle, upper trapezius and middle trapezius with USG in patients diagnosed with impingement and meeting the criteria and healthy volunteers.
Study NCT06666101 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Long chain polyunsaturated Omega-3
Description: 2 capsules of fatty acids in the morning and 2 capsules in the evening except the first day, 4 soft gels in a single administration in the morning, ± 2,6 g/d
Study NCT06666101 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Olive oil
Study NCT06665243 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Technology-enhanced horticultural activities
Description: The indoor technology-enhanced horticultural activities will be delivered to people with dementia and their family caregivers through a smart grower. The smart grower is a hydroponic indoor grower that creates a controllable environment with auto optimization for growing healthy plants, fresh vegetables, herbs, and fruits. A mobile app will be connected to the grower for controlling the growing environment (e.g., lighting, watering), tracking the progress of the plants, and guiding the older people with dementia and their family caregivers in conducting the horticultural activities. The program will consist of eight face-to-face (F-T-F) horticultural activity training sessions for groups of 6-8 participants. The indoor program contains various horticultural, cognitive, and multisensory stimulation activities, such as asking PWD and family caregivers to record the sense of touch and odor when caring for the plants and to observe the various changes in the plants using the smart grower.
Study NCT06666634 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Sentinel node biopsy with either ICG-99mTc-nanoscan or 99mTc-nanoscan
Description: Sentinel node biopsy with either ICG-99mTc-nanoscan or 99mTc-nanoscan
Study NCT06666790 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Scan with elastic scattering spectroscopy device to assess risk of malignancy
Description: Elastic scattering spectroscopy device uses a spectrum of light reflectance to compare suspicious lesion signature to that of previously scanned lesions with known benign or malignant pathology
Study NCT06668415 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hydro dilation
Description: The hydro dilation injections comprises of Depomedrol 80mg and normal saline 0.9%. It is performed under fluoroscopic guidance by the orthopedic surgeon.
Study NCT06668415 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hydro dilation
Description: The hydro dilation injections comprises of Depomedrol 80mg and normal saline 0.9%. It is performed under fluoroscopic guidance by the orthopedic surgeon.
Study NCT06668415 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Spencer muscle energy technique
Description: Spencer muscle energy technique is a seven 7 step procedure which consists of shoulder extension with elbow flexed, shoulder flexion with elbow flexed, circumduction with compression, circumduction with traction, Abduction then adduction with external rotation and glenohumeral pump. Following the complete action, patients will be encouraged to use their muscles for 3 to 5 seconds against little resistance provided by the therapist
Study NCT06668415 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Passive Stretching
Description: The low intensity stretches will be given in supine for all the movements ie Flexion ,Abduction , Internal Rotation and External Rotation for 5 repititions with 30 sec hold.
Study NCT06667206 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Licenced Measles-Rubella vaccine
Description: Licenced Measles-Rubella vaccine provided by the Ugandan EPI programme
Study NCT06666803 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FNB sampling
Description: A supplementary FNB will be performed during the EUS procedure. Sample will be processed to obtain organoids and assess their morphological, proliferative and genetics characteristics.
Study NCT06666803 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: blood sampling
Description: A blood withdrawal will be performed during the EUS procedure. Sample will be processed to assess organoids morphological, proliferative and genetics characteristics.
Study NCT06666894 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intermittent fasting
Description: subjects consumed 100 % of their energy needs in an 8-h period of time each day, with their caloric intake divided into three meals consumed at 1 p.m., 4 p.m., and 8 p.m. The remaining 16 h per 24-h period made up the fasting period. Subjects in the ND group consumed 100 % of their energy needs divided into three meals consumed at 8 a.m., 1 p.m., and 8 p.m. all patients will be subjected to 30 minutes mild aerobic exercise on treadmill.
Study NCT06666894 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dietary approach to stop hypertension (DASH)
Description: The USDA's 2015-2020 Dietary Guidelines for Americans recommend a healthy eating pattern, including a variety of vegetables, fruits, whole grains, fat-free dairy, protein, and oils. Limit saturated fats, trans fats, added sugars, and sodium to less than 10% daily calories, 10% saturated fat daily calories, and 2,300 mg sodium per day.
Study NCT06668844 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic direct Draf IIa
Description: Endoscopic direct Draf IIa (Carolyn' window approach) frontal sinusotomy
Study NCT06668844 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic angled Draf IIa
Description: Group BFrontal sinusotomy using angled endoscopeand instruments
Study NCT06664983 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TPC chemotherapy
Description: The TPC regimen included NAB-paclitaxel administered at a dose of 200 mg/m2 on day 1, cisplatin at a dose of 60 mg/m2 on day 1, and capecitabine at a dose of 1000 mg/m2, taken orally twice a day on days 1 to 14, for each cycle
Study NCT06664983 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cadonilimab combined TPC chemotherapy
Description: Cadonilimab was intravenously given at dose of 10 mg/kg on day 1. The TPC regimen included NAB-paclitaxel administered at a dose of 200 mg/m2 on day 1, cisplatin at a dose of 60 mg/m2 on day 1, and capecitabine at a dose of 1000 mg/m2, taken orally twice a day on days 1 to 14, for each cycle
Study NCT06666478 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise protocol at workspace
Description: The exercise protocol at Workspace begins in a sitting position with spinal mobility exercises that mobilize the hips, lumbar spine, thoracic spine, and cervical spine, accompanied by progressive activation of the peripheral joints in the upper limbs. This is followed by multiaxial functional exercises for the trunk and upper limbs, which combine various movements (e.g., lateral bending and twisting) that simulate the positions employees assume while working.~Subsequently, exercises are performed in an upright position, focusing on stretching and mobilizing the joints and nervous tissue to promote relaxation and release. Coordination, fluid movement, and controlled breathing are emphasized to help workers develop and maintain a stable core while on the job. These principles are essential for workers who are frequently exposed to stressors and physical exertion, as they seek to improve the quality of their movements-namely, smoothness, rhythm, and appropriate speed-while at work.
Study NCT06618690 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise program
Description: A supervised training plan will be carried out for 12 weeks with a frequency of 3 sessions per week with a duration of 60 minutes, an ideal estimate according to the meta-analysis of Montaño-Rojas et al. The first two weeks the group exercises will be performed to familiarize the participants with the exercises and then each participant will perform them at home with a review every two weeks to assess the increase of the load.~The exercises and loads included in this treatment plan have been designed and modified based on previous clinical trials. The training plan will work upper limbs, lower limbs and trunk. All sessions begin with a general warm-up, which will be previously instructed to the participants, in which the heart rate will be increased (see Multimedia Appendix 1). After a two-minute break, the specific block of each session will begin (see Table 1 and Multimedia Appendix 1). All exercises will be performed with dumbbells, elastic bands and a ball.
Study NCT06620640 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intervention will most probably modify activity of neuron networks in specific brain areas responsible for cognitive functions, especially memory consolidation.
Description: Nigth stimulation
Study NCT06620640 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Intervention will most probably modify activity of neuron networks in specific brain areas responsible for cognitive functions, especially memory consolidation.
Description: Nigth stimulation
Study NCT06621836 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ICPB H
Description: ICPB technique The patient's head will be rested on a pillow and turned to the opposite side. A linear probe with higher frequencies will be placed transversely over the midpoint of the SCM muscle. The carotid artery will be identified and traced upwards to its bifurcation. the probe will be then moved laterally to identify the tapering posterolateral end of the SCM muscle. Via an in-plane technique, a 22-gauge, 50 mm needle will be advanced underneath the investing fascia of SCM muscle and above the interscalene groove until feeling the pop on piercing the investing fascia. The patient will be then randomly allocated into two groups (H \& L) using computer-generated random numbers that will be concealed in opaque envelopes. Group H will receive 10 ml 0.25 % bupivacaine he technique will be repeated on the opposite side
Study NCT06621836 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ICPB - L
Description: ICPB technique The patient's head will be rested on a pillow and turned to the opposite side. A linear probe with higher frequencies will be placed transversely over the midpoint of the SCM muscle. The carotid artery will be identified and traced upwards to its bifurcation. the probe will be then moved laterally to identify the tapering posterolateral end of the SCM muscle. Via an in-plane technique, a 22-gauge, 50 mm needle will be advanced underneath the investing fascia of SCM muscle and above the interscalene groove until feeling the pop on piercing the investing fascia. The patient will be then randomly allocated into two groups (H \& L) using computer-generated random numbers that will be concealed in opaque envelopes. Group L will receive 10 ml 0.125% bupivacaine. The technique will be repeated on the opposite side
Study NCT04964934 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Palbociclib
Description: Dosage formulation: palbociclib tablets/capsules will be administered orally
Study NCT05607680 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administered subcutaneously (SC) once a week.
Study NCT04964934 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: Dosage formulation: abemaciclib tablets will be administered orally
Study NCT04964934 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Abemaciclib
Description: Dosage formulation: abemaciclib tablets will be administered orally
Study NCT04964934 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Luteinizing hormone-releasing hormone (LHRH) agonist
Description: Men (when medically applicable) and pre- or peri-menopausal women are required to receive a monthly LHRH agonist.
Study NCT04964934 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Luteinizing hormone-releasing hormone (LHRH) agonist
Description: Men (when medically applicable) and pre- or peri-menopausal women are required to receive a monthly LHRH agonist.
Study NCT04964934 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribociclib
Description: Dosage formulation: ribociclib tablets will be administered orally
Study NCT04964934 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ribociclib
Description: Dosage formulation: ribociclib tablets will be administered orally
Study NCT05607680 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI362
Description: IBI362 administered subcutaneously (SC) once a week.